Dana-Farber’s Belfer Institute for Applied Cancer Science, Evotec sign oncology research deal
The collaboration will focus on validating epigenetic targets for cancer indications and establishing the drugability of the selected target families. Evotec CEO Dr Werner Lanthaler said, "We are
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.